|  |  |
| --- | --- |
|

|  |
| --- |
| **Global Fund COVID-19 Response Mechanism (C19RM)** **Funding Request Form** |

A picture containing drawing  Description automatically generated |

**Date Created:** 6 April 2021

**Date Updated:** 6 April 2021

## Summary Information

|  |  |
| --- | --- |
| **Country (or multicountry)** |  |
| **Principal Recipient(s), grant name(s) and Implementation Period(s)** |  |
| **Planned start and end dates of the C19RM activities by grant**  |  |
| **Currency**  |  |
| **C19RM Base Allocation amount** | **Submission type** | **Amount (US$/EUR)** | **Submission date**  |
| C19RM Fast-track Funding Request[[1]](#footnote-2)  |  |  |
| C19RM Full Funding Request |  |  |
| **Total:**  |  |  |
| **C19RM Above Base Allocation amount[[2]](#footnote-3)** | **Submission type** | **Amount (US$/EUR)** | **Submission date**  |
| C19RM Full Funding Request  |  |  |
| **Total:**  |  |  |

# Section 1. C19RM Fast-track Funding Request (PPE, diagnostics and therapeutics[[3]](#footnote-4) and costs relating to the effective deployment of such health products, including technical assistance)

##  Funding priorities

Provide a brief rationale for the proposed key interventions and activities.

1. Confirm that Global Fund investments are consistent with C19RM Technical Information Notes and Guidelines[[4]](#footnote-5) and applicable WHO guidance (including on COVID-19), and support and align with the intervention categories (i.e. Pillars) within the National Strategic Preparedness and Response Plan for COVID-19 (NSPRP)[[5]](#footnote-6).
2. Indicate the extent to which the national COVID-19 response coordinating bodies, HIV, TB and malaria programs, central medical stores (or equivalent), and laboratory programs were consulted to ensure consistency of the C19RM Fast-track Funding Request with the NSPRP and updated operational and financial gaps, needs and priorities.

|  |
| --- |
| [Applicant response] |

## Program implementation arrangements

1.2.1 Describe the following:

**Implementation Arrangement:** Entities (Principal Recipients, Sub-recipients and other implementing entities) responsible for managing the components requested under the Fast-track Funding Request.

Measures put in place to ensure **efficient program delivery**.

1. **Health products management:** planned mechanisms for the procurement of COVID-19 health products. Describe entities responsible for forecasting/quantification, procurement, storage and distribution and monitoring of supply availability and delivery of COVID-19-specific health products to beneficiaries and service delivery sites (and clarify if these are different from current service delivery points for HIV, TB and malaria). Please include a summary of any foreseen in-country supply chain risks, including any regulatory barriers.

|  |
| --- |
|  [Applicant response] |

## Attachments supporting the C19RM Fast-track Funding Request

|  |  |
| --- | --- |
| [ ]  | C19RM Funding Request Form |
| [ ]  | C19RM Consolidated Budget  |
| [ ]  | Quantification or needs assessment for COVID-19 health products (including contribution and projected pipeline from domestic and other sources of funding) (any format suitable to the applicant) |
| [ ]  | COVID-19 National Testing Strategy, where available |
| [ ] ☐ | C19RM Health Products Management Template (HPMT) per grant |
| [ ]  | CCM Endorsement of the C19RM Fast-track Funding Request[[6]](#footnote-7) |
| [ ]  | Endorsement of fast-track submission by the national COVID-19 response coordinating body |
| [ ]  | National Strategic Preparedness and Response Plan for COVID-19 and budget (ideally for 2021) |

# Section 2. C19RM Full Funding Request

## 2.1 Context

* + 1. Briefly describe the critical elements of the **country context** that informed the development of this funding request by summarizing the:
1. current COVID-19 epidemiological context and its evolution;
2. impact of COVID-19 on the overall health system, and specifically on HIV, TB and malaria;
3. role of civil society in the country’s overall COVID-19 response; and
4. challenges encountered in the COVID-19 response to date.

Reference and attach the following:

1. National Strategic Preparedness and Response Plan for COVID-19 (NSPRP);
2. HIV, TB and malaria mitigation plans; and
3. any other relevant documents.

|  |
| --- |
| [Applicant response] |

* + 1. Summarize which stakeholders have been engaged in the development and decision-making for this Funding Request, including the national HIV, TB and malaria programs, central medical stores (or equivalent), laboratory systems, **civil society and key and vulnerable populations** (including both CCM members and non-CCM community representatives), and communities most severely affected by COVID-19.

|  |
| --- |
| [Applicant response] |

* + 1. Indicate how the **national COVID-19 response coordinating bodies** have been consulted in the development of this request and will be involved in implementation of the proposed C19RM activities.

|  |
| --- |
| [Applicant response] |

## Implementation of C19RM 2020 award (if applicable)

2.2.1 Indicate how much of the previously awarded C19RM funding has been spent and committed and explain how it helped achieve set objectives.

|  |
| --- |
| [Applicant response] |

* + 1. Summarize any issues regarding implementation arrangements, innovations or bottlenecks in service delivery. Please also explain how the C19RM Full Funding Request will address any lessons learned from the implementation of the C19RM 2020 award.

|  |
| --- |
| [Applicant response] |

## Funding Request and prioritization

* + 1. Provide information on disruption of **HIV** **services** (**particularly for key and vulnerable populations)** and describe how identified gaps, challenges and needs are being/will be addressed by the C19RM Full Funding Request and/or through other funding sources (including Global Fund grant funds). *(Where relevant).*

|  |
| --- |
| [Applicant response] |

* + 1. Provide information on disruption of **TB services** (**particularly for key and vulnerable populations**) and describe how identified gaps, challenges and needs, including decline in TB/DR-TB notification, are being/will be addressed by the C19RM Full Funding Request and/or through other funding sources (including Global Fund grant funds). *(Where relevant).*

|  |
| --- |
| [Applicant response] |

* + 1. Provide information on disruption of **malaria services** (case management, vector control and chemoprevention; particularly for key and vulnerable populations) and describe how identified gaps, challenges and needs are being/will be addressed by the C19RM Full Funding Request and/or through other funding sources (including Global Fund grant funds). Specifically, indicate if there is a malaria campaign during this period (IRS, ITN and/or SMC). If so, specify if the relevant PPE and adaptations are part of this funding request or if these are covered through Global Fund grant funds and/or other funding sources, or if there is insufficient funding. *(Where relevant).*

|  |
| --- |
| [Applicant response] |

* + 1. Describe the impact of COVID-19 on **gender-based violence and human rights.** If the C19RM Full Funding Request does not include interventions to respond to identified community, rights and gender (CRG) gaps, challenges and needs, please include details of how they are being separately addressed.

|  |
| --- |
| [Applicant response] |

* + 1. Describe the approach used for the **prioritization of interventions** and activities and link the C19RM Full Funding Request to the pillars of the NSPRP.

|  |
| --- |
| [Applicant response] |

* + 1. Based on the COVID-19 Modular Framework (link forthcoming), provide a brief description/justification for the proposed interventions and key activities in the **C19RM** **Base Allocation** portion of the C19RM Full Funding Request, including expected outcomes of these interventions and how these interventions will support grant targets. These should be in line with the C19RM Technical Information Notes and Guidelines[[7]](#footnote-8), applicable WHO guidance (including on COVID-19) and the NSPRP.

|  |
| --- |
| 1. **COVID-19 control and containment interventions**
 |
| ***Intervention & Key activities***  | *[Enter intervention name in line with the Modular Framework]*1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |
| --- |
| 1. **COVID-19-related risk mitigation measures for programs to fight HIV/AIDS, tuberculosis, and malaria**
 |
| ***Intervention & Key activities*** | ***Mitigation for HIV programs***1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |  |
| --- | --- |
| ***Intervention & Key activities*** | ***Mitigation for TB programs***1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |  |
| --- | --- |
| ***Intervention & Key activities*** | ***Mitigation for Malaria programs***1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |
| --- |
| 1. **Expanded reinforcement of key aspects of health systems and community-led response systems**
 |
| ***Intervention & Key activities*** | *[Enter intervention name in line with the Modular Framework]*1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

* + 1. Provide a brief description/justification for the **high priority** interventions and key activities in the **C19RM Above Base Allocation** **Request**, including expected outcomes of these interventions and how these will support in achieving grant targets. These interventions and key activities should be in line with C19RM Technical Information Notes and Guidelines[[8]](#footnote-9), applicable WHO guidance (including on COVID-19) and the NSPRP.

|  |
| --- |
| 1. **COVID-19 control and containment interventions**
 |
| ***Intervention & Key activities***  | *[Enter intervention name in line with the Modular Framework]*1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |
| --- |
| 1. **COVID-19-related risk mitigation measures for programs to fight HIV/AIDS, tuberculosis, and malaria**
 |
| ***Intervention & Key activities*** | ***Mitigation for HIV programs***1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |  |
| --- | --- |
| ***Intervention & Key activities*** | ***Mitigation for TB programs***1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |  |
| --- | --- |
| ***Intervention & Key activities*** | ***Mitigation for Malaria programs***1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

|  |
| --- |
| 1. **Expanded reinforcement of key aspects of health systems and community-led response systems**
 |
| ***Intervention & Key activities*** | *[Enter intervention name in line with the Modular Framework]*1. *[Enter key activity names in a prioritized order – starting with the highest priority activities]*
 |
| ***Rationale***  | *[Enter a brief rationale for prioritizing these activities]* |
| ***Expected Outcome***  | *[Describe the effect of this intervention/key activities on key affected populations and/or health systems]* |
| ***Expected Investment*** | *[Indicate the proposed Global Fund funding amount for this intervention]* |

## 2.4 Implementation arrangements

* + 1. Describe the proposed **implementation arrangements** and how these will ensure efficient program delivery. Please elaborate on:
1. **Health products management:** planned mechanisms for the procurement of COVID-19 health products. Describe entities responsible for forecasting/quantification, procurement, storage and distribution and monitoring of supply availability and delivery of COVID-19 specific health products to beneficiaries and service delivery sites (and clarify if these are different from current service delivery points for HIV, TB and malaria. Please include a summary of any foreseen in-country supply chain risks, including any regulatory barriers.

|  |
| --- |
| [Applicant response] |

1. **Financial flows**: When funding is received by the Principal Recipient, indicate which other local entities/government departments (if any) will also receive funding for the interventions proposed. Please include a summary of funds flow and internal control risks foreseen (if any).

|  |
| --- |
| [Applicant response] |

1. **Data flows**: The flow of information and reporting from service delivery points. Which entity in the country is responsible for collecting, collating and reporting on national COVID-19 response related programmatic indicators? What mechanisms are in place for the Principal Recipient to engage with this entity and report COVID-19 related data from service delivery sites? Please include a summary of indicators reported, data availability and reporting completeness and data quality risks foreseen (if any).

|  |
| --- |
| [Applicant response] |

1. **Coordination and oversight**: The supervision and oversight mechanisms in place for the national COVID-19 response, including for quantification or needs assessment, procurement, storage and distribution of COVID-19 products. Which type of periodic reporting and monitoring (including community-led monitoring) will be done at each of the following levels: locally, regionally, to the national COVID-19 response taskforce and to the Principal Recipient? How will the CCM and Principal Recipient follow up on progress to implement the planned activities? Please include a summary of the governance and oversight risks foreseen (if any).

|  |
| --- |
| [Applicant response] |

* + 1. Describe the role that **community-based organizations** (CBOs) will play under the implementation arrangements. Please also indicate whether there are opportunities to reinforce the role and effectiveness of CBOs in the national COVID-19 response, including through supporting the most vulnerable communities, community tracing, supported isolation and addressing vaccine hesitancy.

|  |
| --- |
| [Applicant response] |

## Funding landscape, efficiency and sustainability

* + 1. Based on the analysis in the C19RM Funding Landscape Table, describe the funding need and available funding from domestic resources, loans and donor grants for the different components of the health sector response to COVID-19, highlighting major funding gaps. Also, describe how national authorities will work to secure additional funding or new sources of funding for the COVID-19 health response, including any new applications to development banks and other donors that the applicant intends to submit or is pending approval.

|  |
| --- |
| [Applicant response] |

* + 1. Briefly describe how the current government budget and medium-term health budget incorporates additional funding to mitigate the impact of the COVID-19 pandemic, with specific reference to measures taken to ensure that government commitments and plans for domestic financing of HIV, TB and malaria are not adversely impacted.

|  |
| --- |
| [Applicant response] |

* + 1. Explain how the C19RM Full Funding Request reflects value for money, including specifying how the lowest costs of quality inputs required for COVID-19 response will be ensured, how the limited resources will be allocated and utilized strategically to maximize impact and how recurrent costs of Global Fund C19RM capital and system investments will be subsequently sustained by domestic funding.

|  |
| --- |
| [Applicant response] |

## Attachments supporting the C19RM Full Funding Request

Use the list below to verify the completeness of your application package:

|  |  |
| --- | --- |
| [ ]  | C19RM Funding Request Form |
| [ ]  | C19RM Consolidated Budget (including C19RM Above Base Allocation Request) |
| [ ]  | Quantification or needs assessment for COVID-19 health products (including contribution and projected pipeline from domestic and other sources of funding) (any format suitable to the applicant) |
| [ ]  | COVID-19 National Testing Strategy, where available |
| [ ]  | C19RM Health Product Management Template (HPMT) per grant  |
| [ ]  | C19RM Funding Landscape Table  |
| [ ]  | CCM Endorsement of the C19RM Full Funding Request[[9]](#footnote-10) |
| [ ]  | Endorsement by the national COVID-19 response coordinating body of the COVID-19 control and containment interventions of the C19RM Full Funding Request (where relevant) |
| [ ]  | National Strategic Preparedness and Response Plan for COVID-19 and budget (ideally for 2021) |
| [ ]  | HIV, TB and malaria program mitigation plans (where relevant)  |
| [ ]  | List of Civil Society suggestions for inclusion in the C19RM Full Funding Request |
|  | *Add as relevant* |

1. PPE, diagnostics and therapeutics and costs relating to the effective deployment of such health products. [↑](#footnote-ref-2)
2. This is only relevant for the full submission. [↑](#footnote-ref-3)
3. As set out in the optimal category within the Health Product Segmentation Framework (link forthcoming). [↑](#footnote-ref-4)
4. Link forthcoming [↑](#footnote-ref-5)
5. The NSPRP is expected to be available in all countries and ideally updated for 2021. [↑](#footnote-ref-6)
6. <https://www.theglobalfund.org/en/funding-model/applying/materials/>. [↑](#footnote-ref-7)
7. Link forthcoming [↑](#footnote-ref-8)
8. Link forthcoming [↑](#footnote-ref-9)
9. <https://www.theglobalfund.org/en/funding-model/applying/materials/> [↑](#footnote-ref-10)